Chlorpromazine down-regulates tumor necrosis factor-α and attenuates experimental multiple organ dysfunction syndrome in mice

Critical Care Medicine

Volumn 26, Issue 7, 1998, Pages 1244-1250

  Jansen, Monique J J M ^a   Hendriks, Thijs ^a   Knapen, Maarten F C M ^a   Van Kempen, Léon C L T ^a   Van Der Meer, Jos W M ^a   Goris, R Jan A ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Animal model; Chlorpromazine; Cytokines; Generalized inflammation; Intervention; Mouse; Multiple organ dysfunction syndrome; Peritoneal macrophage; Tumor necrosis factor; Zymosan

Indexed keywords

CHLORPROMAZINE; LIPOPOLYSACCHARIDE; TUMOR NECROSIS FACTOR ALPHA; ZYMOSAN;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; INFLAMMATION; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MOUSE; MULTIPLE ORGAN FAILURE; NONHUMAN; ORGAN WEIGHT; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; TEMPERATURE;

EID: 0031864531     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003246-199807000-00029     Document Type: Article

References (25)

1. Baue AE: MOP/MODS, SIRS: An update. Shock 1996; 6(Suppl 1):S1-S5
2. Goris RJ: Shock, sepsis, and multiple organ failure: The result of whole-body inflammation. In: Pathophysiology of Shock, Sepsis, and Organ Failure. Redl H, Schlag G (Eds). Heidelberg, Springer-Verlag, 1995, pp 7-24
3. Members of the American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: American College of Chest Physicians/ Society of Critical Care Medicine Consensus Conference: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992; 20:864-874
4. Deitch EA: Multiple organ failure. Pathophysiology and potential future therapy. Ann Surg 1992; 216:117-134
5. Faist E, Baue AE, Dittmer H, et al: Multiple organ failure in polytrauma patients. J Trauma 1983; 23:775-787
6. Rabinovici R, John R, Esser KM, et al: Serum tumor necrosis factor-alpha profile in trauma patients. J Trauma 1993; 35:698-702
7. Blackwell TS, Christman JW: Sepsis and cytokines: Current status. Br J Anaesth 1996; 77:110-117
8. Glauser MP, Heumann D, Baumgartner JD, et al: Pathogenesis and potential strategies for prevention and treatment of septic shock: An update. Clin Infect Dis 1994; 18(Suppl 2):S205-S216
9. Roumen RM, Hendriks T, van der Ven Jongekrijg J, et al: Cytokine patterns in patients after major vascular surgery, hemorrhagic shock, and severe blunt trauma. Relation with subsequent adult respiratory distress syndrome and multiple organ failure. Ann Surg 1993; 218:769-776
10. Steinberg S, Flynn W, Kelley K, et al: Development of a bacteria-independent model of the multiple organ failure syndrome. Arch Surg 1989; 124:1390-1395
11. Deitch EA, Kemper AC, Specian RD, et al: A study of the relationship among survival, gut-origin sepsis, and bacterial translocation in a model of systemic inflammation. J Trauma 1992; 32:141-147
12. Jansen MJ, Hendriks T, Vogels MT, et al: Inflammatory cytokines in an experimental model for the multiple organ dysfunction syndrome. Crit Care Med 1996; 24:1196-1202
13. Quismorio FP, Bjarnason DF, Kiely WF, et al: Antinuclear antibodies in chronic psychotic patients treated with chlorpromazine. Am J Psychiatry 1975; 132:1204-1206
14. Bertini R, Bianchi M, Mengozzi M, et al: Protective effect of chlorpromazine against the lethality of interleukin 1 in adrenalectomized or actinomycin D-sensitized mice. Biochem Biophys Res Commun 1989; 165:942-946
15. Gadina M, Bertini R, Mengozzi M, et al: Protective effect of chlorpromazine on endotoxin toxicity and TNF production in glucocorticoid-sensitive and glucocorticoid-resistant models of endotoxic shock. J Exp Med 1991; 173: 1305-1310
16. Bertini R, Mengozzi M, Bianchi M, et al: Chlorpromazine protection against interleukin-1 and tumor necrosis factor-mediated activities in vivo. Int J Immunopharmacol 1991; 13:1085-1090
17. Koziol JA, Maxwell DA, Fukushima M, et al: A distribution-free test for tumor-growth curve analyses with application to an animal tumor immunotherapy experiment. Biometrics 1981; 37:383-390
18. Royall JA, Berkow RL, Beckman JS, et al: Tumor necrosis factor and interleukin 1 alpha increase vascular endothelial permeability. Am J Physiol 1989; 257:L399-L410
19. Jansen MJJM, Hendriks T, Verhofstad AAJ, et al: Gradual development of organ damage in the murine zymosaninduced multiple organ dysfunction syndrome. Shock 1997; 8:261-267
20. Bertini R, Wang JM, Mengozzi M, et al: Effects of chlorpromazine on PMN-mediated activities in vivo and in vitro. Immunology 1991; 72:138-143
21. Netea MG, Blok WL, Kullberg BJ, et al: Pharmacologic inhibitors of tumor necrosis factor production exert differential effects in lethal endotoxemia and in infection with live microorganisms in mice. J Infect Dis 1995; 171: 393-399
22. Wang P, Wu P, Siegel MI, et al: IL-10 inhibits transcription of cytokine genes in human peripheral blood mononuclear cells. J Immunol 1994; 153:811-816
23. Tarazona R, Gonzalez Garcia A, Zamzami N, et al: Chlorpromazine amplifies macrophage-dependent IL-10 production in vivo. J Immunol 1995; 154:861-870
24. Jansen MJ, Hendriks T, Huyben CM, et al: Increasing cytotoxic activity and production of reactive oxygen and nitrogen intermediates by peritoneal macrophages during the development of multiple organ dysfunction syndrome in mice. Scand J Immunol 1996; 44:361-368
25. Palacios M, Padron J, Glaria L, et al: Chlorpromazine inhibits both the constitutive nitric oxide synthase and the induction of nitric oxide synthase after LPS challenge. Biochem Biophys Res Commun 1993; 196:280-286